EC to review a recommendation for approving Amgen, UCB’s Evenity for certain osteoporosis

Amgen and UCB said Friday that Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has re-examined and recommended Marketing Authorization for Evenity (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.

Read more

AZ, Amgen: TSLP is an important mediator of inflammation in severe asthma

AstraZeneca and Amgen on Thursday published results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. The trial results were published in the New England Journal of Medicine. The PATHWAY trial achieved its primary efficacy endpoint, showing annual asthma exacerbation rate reductions.

Read more